rs748275416
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000159.4(GCDH):c.1064G>A(p.Arg355His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000093 in 1,613,526 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R355C) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000159.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GCDH | NM_000159.4 | c.1064G>A | p.Arg355His | missense_variant | 10/12 | ENST00000222214.10 | |
GCDH | NM_013976.5 | c.1064G>A | p.Arg355His | missense_variant | 10/12 | ||
GCDH | NR_102316.1 | n.1227G>A | non_coding_transcript_exon_variant | 10/12 | |||
GCDH | NR_102317.1 | n.1445G>A | non_coding_transcript_exon_variant | 9/11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GCDH | ENST00000222214.10 | c.1064G>A | p.Arg355His | missense_variant | 10/12 | 1 | NM_000159.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152132Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 250458Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135632
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461394Hom.: 0 Cov.: 34 AF XY: 0.00000963 AC XY: 7AN XY: 727008
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152132Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74326
ClinVar
Submissions by phenotype
Glutaric aciduria, type 1 Pathogenic:4
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 31, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 13, 2023 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 355 of the GCDH protein (p.Arg355His). This variant is present in population databases (rs748275416, gnomAD 0.006%). This missense change has been observed in individual(s) with glutaric acidemia type I (PMID: 9600243, 9856558, 10699052, 21176883). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 459947). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GCDH protein function with a positive predictive value of 80%. This variant disrupts the p.Arg355 amino acid residue in GCDH. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9711871, 26071121). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 16, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 04, 2022 | Variant summary: GCDH c.1064G>A (p.Arg355His) results in a non-conservative amino acid change located in the C-terminal domain (IPR009075) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 250458 control chromosomes (gnomAD). c.1064G>A has been reported in the literature in several homozygous and compound heterozygous individuals affected with Glutaric Acidemia Type 1 (e.g. Schwartz_1998, Ikeda_1998, Wang_2014, Huishu_2021). These data indicate that the variant is very likely to be associated with disease. At least one publication reported undetectable GCDH activity in cultured fibroblasts isolated from a homozygous patient (Schwartz_1998). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and both of them classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 09, 2023 | Observed in homozygous state or with a second GCDH variant in patients with glutaric aciduria type I in the literature and not observed in homozygous state in controls (PMID: 9600243, 21176883, 24332224, 15505393); Published functional studies demonstrate a damaging effect (PMID: 28062662); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27351573, 32005694, 11058907, 9856558, 20514322, 10699052, 9711871, 32508882, 9600243, 29731766, 35314707, 21176883, 24332224, 15505393, 28062662) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at